These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 20964464)

  • 1. Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
    Scharre DW; Vekeman F; Lefebvre P; Mody-Patel N; Kahler KH; Duh MS
    Drugs Aging; 2010 Nov; 27(11):903-13. PubMed ID: 20964464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study.
    Rege S; Carnahan RM; Johnson ML; Chen H; Holmes HM; Aparasu RR
    Drugs Aging; 2021 Jun; 38(6):493-502. PubMed ID: 33763822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.
    Mauskopf JA; Paramore C; Lee WC; Snyder EH
    J Manag Care Pharm; 2005 Apr; 11(3):231-51. PubMed ID: 15804207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
    Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease.
    Scacchi R; Gambina G; Broggio E; Corbo RM
    Int J Geriatr Psychiatry; 2014 Jun; 29(6):610-5. PubMed ID: 24150894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of rivastigmine use on the risk of nursing home placement in a US sample.
    Beusterien KM; Thomas SK; Gause D; Kimel M; Arcona S; Mirski D
    CNS Drugs; 2004; 18(15):1143-8. PubMed ID: 15581384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].
    Sicras A; Rejas-Gutiérrez J
    Rev Neurol; 2004 Aug 16-31; 39(4):312-6. PubMed ID: 15340887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.
    Suh DC; Thomas SK; Valiyeva E; Arcona S; Vo L
    Drugs Aging; 2005; 22(8):695-707. PubMed ID: 16060719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study.
    Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
    Drugs Aging; 2022 Jun; 39(6):453-465. PubMed ID: 35666463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
    Olazarán J; Carnero-Pardo C; Fortea J; Sánchez-Juan P; García-Ribas G; Viñuela F; Martínez-Lage P; Boada M
    Alzheimers Res Ther; 2023 Aug; 15(1):130. PubMed ID: 37537656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.